Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It is employed to manage high blood pressure and certain forms of heart failure, particularly in patients with reduced ejection fraction or after myocardial infarction.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution networks across Europe, Asia, Africa and the Americas, ensuring consistent quality and regulatory compliance for each shipment globally.

Eplerenone is used in cardiovascular conditions that involve aldosterone‑mediated fluid retention and remodeling. - Hypertension: helps lower blood pressure by reducing sodium and water retention. - Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations by decreasing cardiac remodeling. - Post‑myocardial infarction: lowers risk of cardiovascular death and heart failure progression when added to standard therapy.

Eplerenone may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels, often mild. - Dizziness: feeling light‑headed or unsteady. - Headache: mild to moderate head pain. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects: - Severe hyperkalemia: potentially life‑threatening high potassium requiring medical intervention. - Acute kidney injury: sudden decline in renal function. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Gynecomastia: breast tissue enlargement, reported rarely.

When prescribing Eplerenone, clinicians should consider several precautionary measures to ensure patient safety. - Monitor serum potassium: check baseline and periodic levels to avoid hyperkalemia. - Assess renal function: evaluate creatinine and eGFR before and during therapy. - Avoid use in severe renal impairment: contraindicated when eGFR <30 mL/min. - Caution in patients on potassium‑sparing diuretics or ACE inhibitors: risk of additive potassium rise. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Eplerenone can interact with other medicines that affect potassium balance or renal function.

Major Interactions (Avoid): - ACE inhibitors, ARBs, or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can impair renal clearance and raise potassium. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase eplerenone plasma levels.

Moderate Interactions (Monitor Closely): - Digoxin: altered serum levels may require dose adjustment. - Lithium: concurrent use may increase lithium toxicity. - Antihypertensive agents: additive blood pressure lowering may require monitoring.